The data from the 12 week trial showed phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 showed a reduction in the rate of lung function decline in patients with idiopathic pulmonary fibrosis (IPF).
List view / Grid view
Northwestern Medicine scientists have identified a drug, abemaciclib, that inhibits growth of the most aggressive meningiomas and identified a way to predict recurrence more accurately.
AstraZeneca has announced plans to invest in a new facility, uniting its R&D activities with commercial and corporate functions in Boston, US.
Targeting medicines against the genetic and molecular drivers of lung, breast and other tumours has helped transform cancer care for many patients, yet precision medicine for complex chronic diseases has lagged behind. Maria Orr, Adam Platt and Ben Challis, from BioPharmaceuticals R&D at AstraZeneca, explain why this is changing for…
Takeda’s acquisition of Adaptate Biotherapeutics will enhance efforts to develop cell engager therapies for solid tumours.
A new algorithm uses mass spectrometry data and machine learning to predict whether a molecule has been discovered before, saving drug discovery time and cost.
Here, EPR explores some highlights of the UK’s new Life Sciences Vision for the pharma, biopharma and biotech industries, covering topics from funding to regulatory reviews and clinical trial innovation.
Nathalie Moll, Director General of the European Federation of Pharmaceutical Industries and Associations (EFPIA) gives her take on the industry response to the pandemic; highlighting the benefits of focused effort and what can be achieved through unified collaboration.
The collaborators will use Lycia’s lysosomal targeting chimera (LYTAC) protein degradation platform to develop therapies for five targets across Lilly’s therapeutic areas of focus.
Advanced therapies are a ground-breaking new class of medicines that use gene therapy, cell therapy or tissue engineering to treat disease and injury. Rachel Bell, Trainee Patent Attorney at Marks & Clerk, and Ceri Roberts, Scientific Training Manager – Cellular and Molecular Therapies at NHS Blood and Transplant, discuss some…
Gene therapies could revolutionise management of cardiovascular diseases such as heart failure, according to a GlobalData report.
Bayer to pay $1.5 billion upfront to acquire Viridion Therapeutics, thus strengthening its small molecule capabilities and expanding its reach into new modalities.